Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Debbie Haynes
Vice President, Business Innovation
Debbie joined Sarah Cannon in 2009 and serves as the vice president, business innovation. Her responsibilities include overseeing Sarah Cannon's Personalized Medicine Initiative, support for the Drug Development Program in the UK and alliance management of collaborations with select pharmaceutical partners.
Haynes has more than 18 years of drug development experience. One of her primary areas of expertise is regulatory affairs, including non-clinical and clinical development planning and developing regulatory strategy. She received her bachelor’s degree from Manchester University in England in 1993. Before joining Sarah Cannon Research Institute, she was the regional head of Europe, Middle East and Africa for Genentech UK Ltd.’s Office of International Development.